- Category: Experimental HCV Drugs
- Published on Wednesday, 11 February 2015 00:00
- Written by Achillion
Achillion's next-generation HCV NS5A inhibitor ACH-3102 plus Gilead Science's HCV polymerase inhibitor sofosbuvir (Sovaldi) taken for 6 weeks led to sustained virological response in all previously untreated genotype 1 hepatitis C patients in a small Phase 2 trial, according to a recent company announcement. Achillion now plans to test this same combination taken for just 4 weeks.